



## REGENXBIO to Participate in Upcoming Investor Conferences

February 7, 2018 9:06 PM EST

ROCKVILLE, Md., Feb. 07, 2018 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that it will participate in the following February investor conferences:

### **SunTrust Robison Humphrey 2018 Orphan Drug Day**

**Date:** Tuesday, February 13, 2018

**Location:** JW Marriott Essex House, New York, NY

### **LEERINK Partners 7<sup>th</sup> Annual Global Healthcare Conference**

**Date:** Wednesday, February 14, 2018

**Location:** Lotte New York Palace, New York, NY

**Fireside chat:** Wednesday, February 14, 2018 at 3:30 p.m. ET

A live webcast of the LEERINK fireside chat can be accessed in the Investors section of REGENXBIO's website at [www.regenxbio.com](http://www.regenxbio.com). An archived replay of the webcast will be available on the same website for approximately 30 days following the presentation. In addition, REGENXBIO senior management will be holding one-on-one meetings at each of the conferences.

### **About REGENXBIO**

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV® Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.

### **CONTACT:**

#### **Investors**

Natalie Wildenradt, 646-681-8192

[natalie@argotpartners.com](mailto:natalie@argotpartners.com)

#### **Media**

Adam Pawluk, 202-591-4063

[apawluk@jpa.com](mailto:apawluk@jpa.com)



REGENXBIO Inc.